Published in Gene Therapy Weekly, October 27th, 1997
Research has shown that immunostimulatory ODN containing the CpG motif (CpG ODN) can induce production of a wide variety of cytokines as well as activating B cells, monocytes, dendritic cells, and natural killer (NK) cells.
Expanding on previous research which found that CpG ODN could enhance antibody-dependent cellular cytotoxicity and improve the in vivo efficacy of monoclonal antibody therapy in a syngeneic murine lymphoma model (Blood 1997;89:2994-98), George J. Weiner and colleagues from the University of Iowa and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (1997-10-27)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.